Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 125

Sort by

Sort Order Select

Journal Articles

Outcomes and associated factors after melphalan 140 mg/m² autologous hematopoietic cell transplantation for multiple myeloma in patients over 70 years of age

Aqeeb Ur Rehman, Moazzam Shahzad, Shah Rukh, Zeeshan Sattar, Muhammad Kashif Amin, Jeries Kort, Al-Ola Abdallah, Leyla Shune, Mehdi Hamadani, Joseph McGuirk, Muhammad Umair Mushtaq

Blood (2025) 146 (Supplement 1): 5985.

https://doi.org/10.1182/blood-2025-5985

Published: 2025

Journal Articles

Efficacy of tocilizumab prophylaxis in preventing cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome: A systematic review and meta-analysis

Moazzam Shahzad, Hafiz Muhammad Hannan Javed, Hafsa Shahid, Anas Zayad, Rohan Parvathala, Sarmad Zaman Warraich, Muhammad Umair Mushtaq, Al-Ola Abdallah

Blood (2025) 146 (Supplement 1): 7602.

https://doi.org/10.1182/blood-2025-7602

Published: 2025

Journal Articles

Absolute lymphocyte count (ALC) at apheresis and infusion as a predictor of safety and efficacy for multiple myeloma and B cell malignancies post CAR-T therapy

Raeef Rahman, Isuru Ratnayake, Jianzheng Wu, Lauren Scott, William Wesson, Razan Mansour, Marc Hoffmann, Aung Tun, Joseph Bennett, Al-Ola Abdallah, Muhammad Mushtaq, Dinesh Mudaranthakam, Joseph McGuirk, Nausheen Ahmed, Forat Lutfi

Blood (2025) 146 (Supplement 1): 7630.

https://doi.org/10.1182/blood-2025-7630

Published: 2025

Journal Articles

Parkinsonism and other non-immune effector cell-associated neurotoxicities related to BCMA-directed chimeric antigen receptor T-cell therapy

Paul Worsley, Jianzheng Wu, Isuru Ratnayake, Dinesh Mudaranthakam, Al-Ola Abdallah, Jeries Kort, Evguenia Bhurtel, Leyla Shune, Joseph McGuirk, Muhammad Nashatizadeh, Nausheen Ahmed, Forat Lutfi

Blood (2025) 146 (Supplement 1): 2389.

https://doi.org/10.1182/blood-2025-2389

Published: 2025

Journal Articles

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Blood (2025) 146 (Supplement 1): 5840.

https://doi.org/10.1182/blood-2025-5840

Published: 2025

Journal Articles

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Blood (2025) 146 (Supplement 1): 5820.

https://doi.org/10.1182/blood-2025-5820

Published: 2025

Journal Articles

Predictors of renal recovery in newly diagnosed multiple myeloma with light chain cast nephropathy

Jeet Patel, Jeries Kort, Al-Ola Abdallah, Evguenia Bhurtel, Michael Weise, Jordan Snyder

Blood (2025) 146 (Supplement 1): 2239.

https://doi.org/10.1182/blood-2025-2239

Published: 2025

Journal Articles

Impact of donor age on transplant outcomes in unrelated allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide-based gvhd prophylaxis

Muhammad Kashif Amin, Moazzam Shahzad, Matthew McGuirk, Asma Zakir, Al-Ola Abdallah, Nausheen Ahmed, Sunil Abhyankar, Mehdi Hamadani, Joseph McGuirk, Muhammad Umair Mushtaq

Blood (2025) 146 (Supplement 1): 173.

https://doi.org/10.1182/blood-2025-173

Published: 2025

Journal Articles

Impact of Absolute Lymphocyte Count on Efficacy and Toxicity of T-Cell Engagers in Non-Hodgkin's Lymphoma

Jordan Snyder, Nausheen Ahmed, Aqeeb Ur Rehman, Muhammad Umair Mushtaq, Aung M. Tun, Al-Ola Abdallah, Marc Hoffmann, Forat Lutfi

Blood (2024) 144 (Supplement 1): 7731.

https://doi.org/10.1182/blood-2024-207753

Published: 2024

Journal Articles

Impact of CD34+ Graft Cell Dose on Outcomes after Allogeneic Bone Marrow Transplantation

Sibgha Gull Chaudhary, Moazzam Shahzad, Iqra Anwar, Sohaib Irfan, Muhammad Kashif Amin, Matthew McGuirk, Shaun DeJarnette, Nausheen Ahmed, Al-Ola Abdallah, Sunil Abhyankar, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 7424.

https://doi.org/10.1182/blood-2024-198378

Published: 2024

Journal Articles

Absolute Lymphocyte Count As a Predictor of Safety and Efficacy Post CART for Multiple Myeloma and B Cell Malignancies

Raeef L Rahman, Jianzheng Wu, Lauren N Scott, William Wesson, Razan Mansour, Aung M. Tun, Marc Hoffmann, Al-Ola Abdallah, Dinesh Pal Mudaranthakam, Joseph P. McGuirk, Nausheen Ahmed, Forat Lutfi

Blood (2024) 144 (Supplement 1): 7099.

https://doi.org/10.1182/blood-2024-205978

Published: 2024

Journal Articles

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Blood (2024) 144 (Supplement 1): 7098.

https://doi.org/10.1182/blood-2024-207398

Published: 2024

Journal Articles

Impact of Obesity on Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation

Moazzam Shahzad, Aleenah Mohsin, Aqeeb Ur Rehman, Sohaib Irfan, Muhammad Atif Khan, Muhammad Kashif Amin, Matthew McGuirk, Sibgha Gull Chaudhary, Faiza Humayun Khan, Iqra Anwar, Nausheen Ahmed, Al-Ola Abdallah, Mehdi Hamadani, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 7421.

https://doi.org/10.1182/blood-2024-193485

Published: 2024

Journal Articles

Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Rachel Dileo, Prerna Mewawalla, Gina Patrus, Christopher Strouse, Ethan Chen, Hira Shaikh, James A Davis, Kimberly M Green, Omar Alkharabsheh, Aliya Rashid, Bidushi Pokhrel, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi

Blood (2024) 144 (Supplement 1): 4742.

https://doi.org/10.1182/blood-2024-206059

Published: 2024

Journal Articles

Oncologists' Perspectives and Practices on Minimal Residual Disease Testing in Multiple Myeloma

Fathima Shehnaz Ayoobkhan, Sara Shatnawi, Moazzam Shahzad, Aqeeb Ur Rehman, Sohaib Irfan, Raabia Qureshi, Arooq Khalid, Sibgha Gull Chaudhary, Faiz Anwer, Briha Ansari, Joseph P. McGuirk, Mohamad Mohty, Nausheen Ahmed, Al-Ola Abdallah, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 5045.

https://doi.org/10.1182/blood-2024-203904

Published: 2024

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Jordan Snyder, Chelsea Gorsline, Dilek Ince, Aneela Majeed, Faiz Anwer, Hira Shaikh, Abdullah Mohammad Khan, Al-Ola Abdallah, Kimberly M Green, Shebli Atrash, Claire Yun Kyoung Ryu Tiger, Prerna Mewawalla, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5040.

https://doi.org/10.1182/blood-2024-208349

Published: 2024

Journal Articles

The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

Hannah Katz, Lauren N Scott, Pilar Thangwaritorn, Jianzheng Wu, William Wesson, Dinesh Pal Mudaranthakam, Shaun DeJarnette, Al-Ola Abdallah, Marc Hoffmann, Forat Lutfi, Sunil Abhyankar, Leyla O. Shune, Muhammad Umair Mushtaq, Anurag Singh, Haitham Abdelhakim, Joseph P. McGuirk, Muhammad Mahdi Nashatizadeh, Liz Muenks, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5030.

https://doi.org/10.1182/blood-2024-199312

Published: 2024

Journal Articles

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial

Ishita Kamboj, Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, James A Davis, Aliya Rashid, Kevin Graf, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Al-Ola Abdallah, Shebli Atrash, Abdullah Mohammad Khan, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 2411.2.

https://doi.org/10.1182/blood-2024-199187

Published: 2024

Journal Articles

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Abdullah Mohammad Khan, Al-Ola Abdallah, Nausheen Ahmed, Shebli Atrash, Manisha Bhutani

Blood (2024) 144 (Supplement 1): 2404.

https://doi.org/10.1182/blood-2024-208692

Published: 2024

Journal Articles

Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Patients with Light-Chain Amyloidosis: A Systematic Review and Meta-Analysis

Moazzam Shahzad, Zobia Farooq, Amina Akram, Ben Ponvilawan, Rimsha Riaz, Mashood Ahmad Farooqi, Saba Ambreen Awan, Sibgha Gull Chaudhary, Iqra Anwar, Shajadi Patan, Muhammad Kashif Amin, Leyla O. Shune, Al-Ola Abdallah, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 4670.

https://doi.org/10.1182/blood-2024-203194

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Outcomes and associated factors after melphalan 140 mg/m² autologous hematopoietic cell transplantation for multiple myeloma in patients over 70 years of age

Efficacy of tocilizumab prophylaxis in preventing cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome: A systematic review and meta-analysis

Absolute lymphocyte count (ALC) at apheresis and infusion as a predictor of safety and efficacy for multiple myeloma and B cell malignancies post CAR-T therapy

Parkinsonism and other non-immune effector cell-associated neurotoxicities related to BCMA-directed chimeric antigen receptor T-cell therapy

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Predictors of renal recovery in newly diagnosed multiple myeloma with light chain cast nephropathy

Impact of donor age on transplant outcomes in unrelated allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide-based gvhd prophylaxis

Impact of Absolute Lymphocyte Count on Efficacy and Toxicity of T-Cell Engagers in Non-Hodgkin's Lymphoma

Impact of CD34+ Graft Cell Dose on Outcomes after Allogeneic Bone Marrow Transplantation

Absolute Lymphocyte Count As a Predictor of Safety and Efficacy Post CART for Multiple Myeloma and B Cell Malignancies

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Impact of Obesity on Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation

Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Oncologists' Perspectives and Practices on Minimal Residual Disease Testing in Multiple Myeloma

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns

The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Patients with Light-Chain Amyloidosis: A Systematic Review and Meta-Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only